Researchers Seeking Volunteers for Study Exploring Early Stages of Alzheimer's Disease
Dean Foundation begins study of investigational medication to target earliest phase of the disease.
Madison, WI – Approximately 5.3 million adults in the United States suffer from Alzheimer's disease, and the numbers are expected to double by 2050. There is no cure for Alzheimer's disease; however, there are approved medications to treat some of the symptoms.
Clinical researchers with the Dean Foundation are now exploring the earliest phase of the illness, called prodromal Alzheimer's disease. During this stage, patients have memory loss or mild cognitive impairment (MCI) along with spinal fluid abnormalities suggestive of Alzheimer's disease. This is the first large-scale clinical research trial to include only individuals with both early memory loss and a spinal fluid biomarker consistent with Alzheimer's.
"By investigating the potential onset of the disease at it's earliest stage, we are hoping to understand more and provide new treatments to help people in the beginning stages," says Dr. Leslie Taylor, Dean Psychiatrist and Study Principal Investigator. "Once damage has been done to the brain, we can't do anything about it. We are looking to keep that from happening in the first place.
This Phase II clinical research study is designed to assess the safety and tolerability of BMS-708163 (Bristol-Meyers Squibb), an investigational medication for prodromal Alzheimer's disease.
The study is being conducted in approximately 70 sites in North America and Europe. Study volunteers may receive study-related medical care, study medication, laboratory testing, and cognitive testing. Medical insurance is not necessary to participate in this study, In addition, reimbursement for travel may be available. People appropriate for this study have impairment in functioning that is noticeable by themselves and others and are between the ages of 45-90. Study participants must have a consistent study partner to accompany them to all visits.
For more information on enrolling in this study contact JoAnn with the Dean Foundation at (608) 827-2333, and mention study 554.
